Scalper1 News
Rare-disease specialist Raptor Pharmaceuticals (RPTP) was up Friday, after it announced a buyout late Thursday that brings it into the field of cystic fibrosis. Raptor Pharmaceuticals inked a deal with privately held Tripex Pharmaceuticals to acquire Quinsair, an inhaled drug that helps manage chronic pulmonary infections that are common in CF patients. The drug has been approved in the European Union and Canada, though it hasn’t yet been Scalper1 News
Scalper1 News